Skip to main content

Advertisement

Table 2 Primary treatment modalities and responses in patients with ENKTL

From: Prognostic role of ABO blood type in patients with extranodal natural killer/T cell lymphoma, nasal type: a triple-center study

Characteristic Total (cases) Blood four-type group [cases (%)] P Blood two-type group [cases (%)] P
O A B AB O Non-O
Treatment modality       0.701    0.690
 CT combined RT 436 164 (64.3) 118 (60.5) 120 (63.8) 34 (57.6)   164 (64.3) 272 (61.5)  
 CT alone 171 57 (22.4) 49 (25.1) 47 (25.0) 18 (30.5)   57 (22.4) 114 (25.8)  
 RT alone 72 26 (10.2) 23 (11.8) 16 (8.5) 7 (11.9)   26 (10.2) 46 (10.4)  
 Best supportive care 18 8 (3.1) 5 (2.6) 5 (2.7) 0 (0)   8 (3.1) 10 (2.3)  
CT regimen       0.675    0.534
 CHOP or CHOP-like 218 73 (28.6) 68 (34.9) 61 (32.4) 16 (27.1)   73 (28.6) 145 (32.8)  
 EPOCH 105 43 (16.9) 24 (12.3) 32 (17.0) 6 (10.2)   43 (16.9) 62 (14.0)  
 ATT 43 15 (5.9) 13 (6.7) 12 (6.4) 3 (5.1)   15 (5.9) 28 (6.3)  
 GEMOX + L-asp 232 85 (33.3) 61 (31.3) 60 (31.9) 26 (44.1)   85 (33.3) 147 (33.3)  
 SMILE 9 5 (2.0) 1 (0.4) 2 (1.1) 1 (0.4)   5 (2.0) 4 (0.9)  
Complete response 509 202 (79.2) 133 (68.2) 131 (69.7) 43 (72.9) 0.040 202 (79.2) 307 (69.5) 0.005
  1. CT chemotherapy, RT radiotherapy, CHOP cyclophosphamide + doxorubicin + vincristine + prednisone, EPOCH etoposide + doxorubicin + vincristine + cyclophosphamide + prednisone, ATT alternating triple therapy (CHOP-B, cyclophosphamide + doxorubicin + vincristine + bleomycin + prednisone, IMVP-16 ifosfamide + methotrexate + etoposide; DHAP, dexamethasone + cisplatin + cytarabine), GEMOX + L-asp gemcitabine + oxaliplatin + l-asparaginase, SMILE dexamethasone + methotrexate + ifosfamide + l-asparaginase + etoposide